Methotrexaat Basic Pharma

Methotrexate, the active ingredient in Methotrexaat Basic Pharma, is an antimetabolite presented as various strengths injectable formulation for subcutaneous use. It treats autoimmune disorders such as rheumatoid arthritis and psoriasis, and is also employed in certain cancers and gestational trophoblastic disease. GNH USA supplies Methotrexaat Basic Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexaat Basic Pharma (methotrexate) is employed across several disease families where it modulates immune activity and cell proliferation. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Gestational trophoblastic disease: targets proliferating trophoblastic tissue to induce remission.

Methotrexaat Basic Pharma may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue or malaise - Oral mucosal ulceration - Transient elevation of liver enzymes - Mild cytopenias (e.g., reduced white blood cells) - Alopecia (hair thinning)

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Life‑threatening infections due to bone‑marrow suppression - Acute renal failure - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Myelosuppression leading to pancytopenia

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Pregnancy: contraindicated (Category X); ensure effective contraception. - Renal function: assess creatinine clearance; dose adjust or avoid if impaired. - Hepatic function: monitor liver enzymes regularly; avoid in severe hepatic disease. - Infection risk: defer treatment in active infections and monitor for opportunistic pathogens. - Concomitant immunosuppressants: use with caution and increase monitoring frequency. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexaat Basic Pharma interacts with several drug classes that can modify its safety profile.

Major Interactions (Avoid): - Non‑selective NSAIDs: increase methotrexate toxicity. - High‑dose penicillins: may raise plasma methotrexate levels. - Proton‑pump inhibitors: can reduce renal clearance of methotrexate. - Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: potential additive bone‑marrow suppression. - Azathioprine or other immunosuppressants: heightened risk of cytopenias. - Folic acid supplements: may diminish efficacy if not timed appropriately.